Trebananib

Drug Profile

Trebananib

Alternative Names: 20060439; AMG-386

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Takeda
  • Class Antibodies; Antineoplastics; Peptides; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin-1 inhibitors; Angiopoietin-2 inhibitors; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Breast cancer; Hepatocellular carcinoma; Renal cell carcinoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Solid tumours
  • No development reported Colorectal cancer; Gastric cancer; Oesophageal cancer

Most Recent Events

  • 01 Dec 2016 Amgen completes the global phase III TRINOVA-1 trial for Ovarian, Fallopian tube and Peritoneal cancers (Combination therapy, Second-line therapy or greater) (NCT01204749)
  • 24 Jun 2016 Takeda terminates its licence for trebananib in Japan
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top